Novartis: Reclast highly effective in reducing osteoporosis fractures

By E. Janene Geiss

Philadelphia, Sept. 18 - Novartis AG said Saturday that new phase 3 data presented for the first time demonstrated that the investigational treatment Reclast (zoledronic acid) 5 mg was highly effective in reducing the incidence of bone fracture in women with postmenopausal osteoporosis across the most common fracture sites - hip, spine and non-spine - with sustained effect over three years.

Further data demonstrated that postmenopausal osteoporosis patients currently taking oral alendronate can be directly switched to Reclast and maintain beneficial bone effects for a full 12 months after a single dose, according to a news release from the Basel, Switzerland, pharmaceutical company.

These studies were presented Saturday at the annual meeting of the American Society of Bone and Mineral Research in Philadelphia.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.